1
|
Markman M: Chemoradiation in the
management of cervix cancer: current status and future directions.
Oncology. 84:246–250. 2013. View Article : Google Scholar : PubMed/NCBI
|
2
|
Hemaiswarya S and Doble M: Combination of
phenylpropanoids with 5-fluorouracil as anti-cancer agents against
human cervical cancer (HeLa) cell line. Phytomedicine. 20:151–158.
2013. View Article : Google Scholar : PubMed/NCBI
|
3
|
Yamamoto K, Fujiwara Y, Nishida T, et al:
Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for
advanced gastric cancer. Anticancer Res. 29:4211–4215.
2009.PubMed/NCBI
|
4
|
Osaka Y, Shinohara M, Hoshino S, Ogata T,
Takagi Y, Tsuchida A and Aoki T: Phase II study of combined
chemotherapy with docetaxel, CDDP and 5-FU for highly advanced
esophageal cancer. Anticancer Res. 31:633–638. 2011.
|
5
|
Nagata M, Nakayama H, Tanaka T, et al:
Overexpression of cIAP2 contributes to 5-FU resistance and a poor
prognosis in oral squamous cell carcinoma. Br J Cancer.
105:1322–1330. 2011. View Article : Google Scholar : PubMed/NCBI
|
6
|
Wang CJ, Stratmann J, Zhou ZG and Sun XF:
Suppression of microRNA-31 increases sensitivity to 5-FU at an
early stage, and affects cell migration and invasion in HCT-116
colon cancer cells. BMC Cancer. 10:6162010. View Article : Google Scholar : PubMed/NCBI
|
7
|
Karasawa H, Miura K, Fujibuchi W, et al:
Down-regulation of cIAP2 enhances 5-FU sensitivity through the
apoptotic pathway in human colon cancer cells. Cancer Sci.
100:903–913. 2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
Lin G, Lin MC, Lin S, et al: Early growth
response protein-1 promoter-mediated synergistic antitumor effect
of hTERTC27 gene therapy and 5-fluorouracil on nasopharyngeal
carcinoma. Cancer Biother Radiopharm. 27:434–441. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Gomez DE, Armando RG, Farina HG, Menna PL,
Cerrudo CS, Ghiringhelli PD and Alonso DF: Telomere structure and
telomerase in health and disease (Review). Int J Oncol.
41:1561–1569. 2012.PubMed/NCBI
|
10
|
Shay JW and Wright WE: Role of telomeres
and telomerase in cancer. Semin Cancer Biol. 21:349–353. 2011.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Ruden M and Puri N: Novel anticancer
therapeutics targeting telomerase. Cancer Treat Rev. 39:444–456.
2013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Podlevsky JD and Chen JJ: It all comes
together at the ends: telomerase structure, function, and
biogenesis. Mutat Res. 730:3–11. 2012. View Article : Google Scholar : PubMed/NCBI
|
13
|
Huang JJ, Lin MC, Bai YX, et al: Ectopic
expression of a COOH-terminal fragment of the human telomerase
reverse transcriptase leads to telomere dysfunction and reduction
of growth and tumorigenicity in HeLa cells. Cancer Res.
62:3226–3232. 2002.
|
14
|
Huang J, Bai YX, Han SW, et al: A human
TERT C-terminal polypeptide sensitizes HeLa cells to
H2O2-induced senescence without affecting
telomerase enzymatic activity. Biochem Biophys Res Commun.
301:627–632. 2003. View Article : Google Scholar : PubMed/NCBI
|
15
|
Ng SS, Gao Y, Chau DH, et al: A novel
glioblastoma cancer gene therapy using AAV-mediated long-term
expression of human TERT C-terminal polypeptide. Cancer Gene Ther.
14:561–572. 2007. View Article : Google Scholar : PubMed/NCBI
|
16
|
Gao Y, Ng SS, Chau DH, et al: Development
of recombinant adeno-associated virus and adenovirus cocktail
system for efficient hTERTC27 polypeptide-mediated cancer gene
therapy. Cancer Gene Ther. 15:723–732. 2008. View Article : Google Scholar : PubMed/NCBI
|
17
|
Lin G, Zhao L, Yin F, et al: TCF3 inhibits
F9 embryonal carcinoma growth by the down-regulation of Oct4. Oncol
Rep. 26:893–899. 2011.PubMed/NCBI
|
18
|
Afzal S, Jensen SA, Vainer B, et al: MTHFR
polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal
cancer. Ann Oncol. 20:1660–1666. 2009. View Article : Google Scholar : PubMed/NCBI
|
19
|
Lü MH, Liao ZL, Zhao XY, et al:
hTERT-based therapy: A universal anticancer approach (Review).
Oncol Rep. 28:1945–1952. 2012.PubMed/NCBI
|
20
|
Elmore S: Apoptosis: a review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
21
|
García-Sáez AJ: The secrets of the Bcl-2
family. Cell Death Differ. 19:1733–1740. 2012.
|
22
|
Ola MS, Nawaz M and Ahsan H: Role of Bcl-2
family proteins and caspases in the regulation of apoptosis. Mol
Cell Biochem. 351:41–58. 2011. View Article : Google Scholar : PubMed/NCBI
|
23
|
Porter AG and Jänicke RU: Emerging roles
of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Würstle ML, Laussmann MA and Rehm M: The
central role of initiator caspase-9 in apoptosis signal
transduction and the regulation of its activation and activity on
the apoptosome. Exp Cell Res. 318:1213–1220. 2012.
|
25
|
Rosen A and Casciola-Rosen L:
Macromolecular substrates for the ICE-like proteases during
apoptosis. J Cell Biochem. 64:50–54. 1997. View Article : Google Scholar : PubMed/NCBI
|